Baker Brothers Investments

Baker Bros. Advisors LP serves as the discretionary investment manager to private pooled investment funds organized primarily as limited partnerships and restricted to accredited and qualified purchasers; its investor base is principally institutional, including foundations and endowments, and only certain funds are open to new investors. The Firm provides portfolio management across public and private securities, derivative instruments, royalty and asset-backed streams, and cash management investments in the life sciences and health care sectors.

The Firm pursues a fundamentally driven, life-sciences–focused strategy that typically builds large, concentrated, long‑term positions and often seeks active engagement with company management, including board participation. Investment decisions are made by an Investment Committee informed by internal scientific and medical expertise and primary research, and the Firm generally manages client portfolios on a fully discretionary basis rather than tailoring investments to individual limited partners.

Compared with many peers, Baker Bros. is notable for managing a sizable pool of capital (over $28 billion of RAUM) while maintaining a sector-specialized, high‑concentration approach and a documented practice of using bundled commission arrangements (a formal commission‑sharing aggregator) to pay for research and related services, including travel and conference expenses. The brochure also discloses several operational practices that can create unusual conflicts — for example, employees sometimes serve on portfolio company boards and cash or equity received in such roles is funneled to the firm to offset future management fees, and the Firm has arrangements to finance employee option exercises with proceeds that may reduce future fees — all of which the Firm says are managed through policies and allocation procedures.